495 related articles for article (PubMed ID: 15755896)
1. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
3. Advances in biology of multiple myeloma: clinical applications.
Hideshima T; Bergsagel PL; Kuehl WM; Anderson KC
Blood; 2004 Aug; 104(3):607-18. PubMed ID: 15090448
[TBL] [Abstract][Full Text] [Related]
4. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
5. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
Bergsagel PL; Kuehl WM
Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
Maura F; Bergsagel PL
Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
[TBL] [Abstract][Full Text] [Related]
8. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
[TBL] [Abstract][Full Text] [Related]
10. Chromosome translocations in multiple myeloma.
Bergsagel PL; Kuehl WM
Oncogene; 2001 Sep; 20(40):5611-22. PubMed ID: 11607813
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing primary and secondary translocations in multiple myeloma.
Gabrea A; Leif Bergsagel P; Michael Kuehl W
DNA Repair (Amst); 2006 Sep; 5(9-10):1225-33. PubMed ID: 16829212
[TBL] [Abstract][Full Text] [Related]
12. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
13. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
14. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
15. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.
Miura K; Iida S; Hanamura I; Kato M; Banno S; Ishida T; Kusumoto S; Takeuchi G; Miwa H; Nitta M; Inagaki H; Eimoto T; Nomura K; Taniwaki M; Ueda R
Cancer Sci; 2003 Apr; 94(4):350-4. PubMed ID: 12824903
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
17.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
18. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
Takimoto M; Ogawa K; Kato Y; Saito T; Suzuki T; Irei M; Shibuya Y; Suzuki Y; Kato M; Inoue Y; Takahashi M; Sugimori H; Miura I
Int J Hematol; 2008 Apr; 87(3):260-5. PubMed ID: 18274833
[TBL] [Abstract][Full Text] [Related]
19. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.
Büschges R; Weber RG; Actor B; Lichter P; Collins VP; Reifenberger G
Brain Pathol; 1999 Jul; 9(3):435-42; discussion 432-3. PubMed ID: 10416984
[TBL] [Abstract][Full Text] [Related]
20. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.
Wlodarska I; Dierickx D; Vanhentenrijk V; Van Roosbroeck K; Pospísilová H; Minnei F; Verhoef G; Thomas J; Vandenberghe P; De Wolf-Peeters C
Blood; 2008 Jun; 111(12):5683-90. PubMed ID: 18391076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
